LUCID Partners With Japanese Pharmaceutical Company To Develop Personalized Music Treatment For Alzheimer’s Disease

LUCID and Japan Tobacco Inc. (JT) are partnering on the development of a prescription digital therapeutic for Alzheimer’s disease. The digital therapeutic, called LUC-101, uses personalized music treatment to reduce agitation and anxiety in dementia care. JT is providing funding for LUCID to conduct research and continue developing the digital therapeutic.

With LUC-101, LUCID strives to deliver the benefits of personalized music therapy for Alzheimer’s while lowering the overall cost and barrier to entry through artificial intelligence (AI) technology and cloud-enabled applications. Sheridan College’s Centre for Elder Research is also involved in the development . . .